| abstract |
The present invention relates to a compound of formula I, [Chemical 1] Or a pharmaceutically acceptable acid addition salt thereof, wherein Q is oxygen or sulfur, X is -C (R 4c ) =, or -N =, R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, Substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle, R 2 is hydrogen, optionally one to three fluoro substituents, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or C 1 -C 3 alkyl substituted with a group of formula II; [Chemical 2] R 3 is hydrogen or C 1 -C 3 alkyl, R 4a and R 4b are independently hydrogen, halo, or C 1 -C 4 alkyl optionally substituted with one to three fluoro substituents, When X is -C (R 4c ) =, R 4c is hydrogen, halo, or C 1 -C 4 alkyl optionally substituted with one to three fluoro substituents; R 5 is hydrogen or C 1 -C 3 alkyl optionally substituted with one to three fluoro substituents, With the proviso that R 6 only when R 5 is other than hydrogen is C 1 -C 3 alkyl, R 6 is C 1 -C 3 alkyl substituted with three fluoro substituents from one hydrogen or optionally And R 7 is hydrogen or C 1 -C 6 alkyl optionally substituted with one to three halogen substituents; n is an integer from 1 to 6. The compounds of the present invention are effective in activating 5-HT1F receptors, inhibiting extravasation of neuroproteins, and treating or preventing migraine in mammals, particularly humans. |